GC101 for muscular atrophy, spinal

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Feb 2023: Trial started, NCT05824169
  2. 21 Apr 2023: Trial registered, NCT05824169

The trials

NCT05824169: Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

State
Under way
Phase
Phase 1 and Phase 2
People
18 planned
Started
25 Feb 2023
Primary completion
Dec 2026
Arms
Low dosage group, High dosage group
Results
None posted
  1. 25 Feb 2023: Trial started
  2. 21 Apr 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.